Page last updated: 2024-08-17

quinidine and paroxetine

quinidine has been researched along with paroxetine in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (14.29)18.2507
2000's8 (28.57)29.6817
2010's15 (53.57)24.3611
2020's1 (3.57)2.80

Authors

AuthorsStudies
Topliss, JG; Yoshida, F1
Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J1
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Dalvie, D; Loi, CM; Smith, DA1
Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS1
Bellman, K; Knegtel, RM; Settimo, L1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Colado, MI; Green, AR; Williams, JL1
Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P1
Clement, EM; Elliott, JM; Grahame-Smith, DG1
Lurcott, G1
Bertelsen, KM; Greenblatt, DJ; Obach, RS; Venkatakrishnan, K; Von Moltke, LL1
Katoh, M; Nakajima, M; Sawada, T; Soeno, Y; Tateno, C; Yokoi, T; Yoshizato, K1
Castberg, I; Davies, SJ; Lennard, MS; Lewis, G; Spigset, O; Taylor, S; Westin, AA1
Pope, LE; Schoedel, KA; Sellers, EM1
Achanti, S; Katta, RR1
Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S1
Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC1

Reviews

2 review(s) available for quinidine and paroxetine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone.
    Anesthesia progress, 1998,Fall, Volume: 45, Issue:4

    Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Binding, Competitive; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Fluoxetine; Humans; Hydrocodone; Oxycodone; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors

1998

Trials

1 trial(s) available for quinidine and paroxetine

ArticleYear
Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
    Clinical drug investigation, 2012, Mar-01, Volume: 32, Issue:3

    Topics: Adult; Affective Symptoms; Dextromethorphan; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Middle Aged; Paroxetine; Quinidine

2012

Other Studies

25 other study(ies) available for quinidine and paroxetine

ArticleYear
QSAR model for drug human oral bioavailability.
    Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

    Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000
Inhibition of P-glycoprotein by newer antidepressants.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:1

    Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection

2003
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Journal of medicinal chemistry, 2004, Feb-26, Volume: 47, Issue:5

    Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Which metabolites circulate?
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:5

    Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations

2013
MICE models: superior to the HERG model in predicting Torsade de Pointes.
    Scientific reports, 2013, Volume: 3

    Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes

2013
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
    Pharmaceutical research, 2014, Volume: 31, Issue:4

    Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation

2014
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    British journal of pharmacology, 1995, Volume: 115, Issue:7

    Topics: 3,4-Methylenedioxyamphetamine; Animals; Body Temperature Regulation; Brain; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Female; Fever; Humans; Hydroxyindoleacetic Acid; Male; Mixed Function Oxygenases; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Phenotype; Proadifen; Quinidine; Rats; Rectum; Serotonin; Serotonin Agents; Sex Factors; Tritium

1995
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
    European journal of clinical pharmacology, 1998, Volume: 54, Issue:3

    Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline

1998
Investigation of the presynaptic effects of quinine and quinidine on the release and uptake of monoamines in rat brain tissue.
    Neuropharmacology, 1998, Volume: 37, Issue:7

    Topics: Animals; Biogenic Monoamines; Brain; Dopamine; In Vitro Techniques; Male; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Presynaptic Terminals; Quinidine; Quinine; Rats; Rats, Sprague-Dawley; Serotonin; Synaptosomes

1998
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
    Drug metabolism and disposition: the biological fate of chemicals, 2003, Volume: 31, Issue:3

    Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Humans; Microsomes, Liver; Paroxetine; Quinidine

2003
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.
    Journal of pharmaceutical sciences, 2007, Volume: 96, Issue:2

    Topics: Adrenergic Agents; Animals; Chimera; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Drug Interactions; Humans; Infant; Liver; Male; Mice; Mice, SCID; Models, Animal; Paroxetine; Quinidine; Urokinase-Type Plasminogen Activator

2007
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies.
    Acta psychiatrica Scandinavica, 2010, Volume: 122, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Antifungal Agents; Antimalarials; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Clopenthixol; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Fluoxetine; Humans; In Vitro Techniques; Ketoconazole; Male; Methotrimeprazine; Microsomes, Liver; Middle Aged; Paroxetine; Quinidine

2010
High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study.
    Journal of food and drug analysis, 2016, Volume: 24, Issue:4

    Topics: Animals; Chromatography, Liquid; Paroxetine; Quinidine; Rats; Reproducibility of Results; Tandem Mass Spectrometry

2016
Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
    Biopharmaceutics & drug disposition, 2018, Volume: 39, Issue:1

    Topics: Ciprofloxacin; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Fluconazole; Humans; Itraconazole; Ketoconazole; Models, Biological; Paroxetine; Quinidine; Rifampin; Software

2018
Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
    Drug metabolism and bioanalysis letters, 2022, Volume: 15, Issue:1

    Topics: Alleles; Catalysis; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Fluoxetine; Ligands; Molecular Docking Simulation; Paroxetine; Quinidine; Terbinafine

2022